Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Dallixa® Eyelash Serum in Idiopathic Eyelash Hypotrichosis
NCT07776028Phase 4Completed
- Sponsor
- Quantum Aesthetics
- Start
- Aug 2025
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial in idiopathic eyelash hypotrichosis, sponsored by Quantum Aesthetics. Primary endpoint: Proportion of subjects with >= 1-grade increase in the Global Eyelash Assessment at 4 months. Started Aug 2025; status: completed.
02
Conditions
idiopathic eyelash hypotrichosis
Beyond the preview
Go deeper on NCT07776028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07776028.